Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels

Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer. Dose reduction of erlotinib in patients with severe hepatic impairment has been established. We pr...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Czejka, M., Sahmanovic, A., Buchner, P., Steininger, T., Dittrich, C.
Médium: Artigo
Jazyk:Inglês
Vydáno: S. Karger AG 2013
Témata:
Published online: December, 2013
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901587/
https://ncbi.nlm.nih.gov/pubmed/24474924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000357211
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky